Journal: bioRxiv
Article Title: Telomerase modRNA offers a novel RNA-based approach to treat human pulmonary fibrosis
doi: 10.1101/2025.02.19.639041
Figure Lengend Snippet: A Schematic presentation of the modRNA hTERT template. B The modRNA production is divided into three main steps: the sequence design, then in vitro transcription (IVT) where the modRNA is generated and lastly the purification step. C Schematic describing experimental setup used to validate transfection efficiency of modRNA GFP and functionality of modRNA hTERT. D Transmission electron microscopy of ATII cells. Arrowheads indicate lamellar body like structures. Nucleus is depicted as n. E Fold change of hTERT mRNA expression in ATII cells transfected with modRNA hTERT in a concentration range of 0.25 – 2 µg/mL compared to modRNA GFP 2 µg/mL control (modRNA control) after 24 h and 48 h (n = 3). F TRAP assay revealed reactivation of telomerase activity in ATII cells after 24 h and 48 h in dose-dependent effect. Positive (pos.) control = human induced pluripotent stem cells, negative (neg.) control = HUVEC cells, LB = lysis buffer, 1 = cell lysate, Δ = heat inactivated lysate. G Quantification of TRAP assays indicates a dose-dependent increase of telomerase activity compared to modRNA control (n = 3). H No prolonged immune reaction was detected after 48 h modRNA treatment in ATII cells compared to untreated control (n = 3). *p<0.05; ***p<0.001; Two-way ANOVA, Dunnett’s multiple comparisons test.
Article Snippet: Human primary ATII cells (EP71AL Epithelix) were obtained from non-smoking donors with no reported pathology (Epithelix Sarl, Geneva, Switzerland).
Techniques: Sequencing, In Vitro, Generated, Purification, Transfection, Transmission Assay, Electron Microscopy, Expressing, Concentration Assay, Control, TRAP Assay, Activity Assay, Lysis